{"doi":"10.1002/jcph.1641","title":"TMPRSS2: Potential Biomarker for COVID‐19 Outcomes","abstract":"Coronavirus disease 2019 (COVID-19) clinical data has so far shown that the mortality rate for men is higher than for women. This disparity is observed worldwide and across different ethnic/racial groups (Table 1). Early reports from Italy and Germany show that while infection rates are similar between sexes, nearly 70% and 65%, respectively, of deaths are males. In New York City, an epicenter of the US outbreak, 54% of those infected are men, yet men account for 63% of deaths. Epidemiologic data from the previous coronavirus infections, severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), also indicated sex-based differences in disease susceptibility and outcomes. This discrepancy was attributed to many factors, including smoking, immune differences, and other comorbidities. An initial report released by the Centers for Disease Control and Prevention (CDC) on population-based surveillance sampled across 14 states, representing 10% of the US population, has indicated that age and comorbidities are associated with increased hospitalization rates of patients with COVID-19.1 The data on sex also suggest sexual dimorphism consistent with reports from other countries (Table 1). The preliminary data on race suggest that minority populations may be disproportionately impacted by the coronavirus, where blacks contributed to 33% of the hospitalizations despite representing only 18% of the sampled population. As more data become available, correlations between race and disease severity can be interrogated more thoroughly, including the role of socioeconomic factors on influencing this disparity. Investigations into the genetic and molecular differences between women and men are warranted to identify relevant biomarkers for disease susceptibility and outcomes. Based on data from literature, we propose a novel mechanism of the observed sex differences in clinical outcomes in patients and identify a role for the transmembrane protease serine 2 (TMPRSS2) as a contributing factor to the more severe outcomes noted for COVID-19. The angiotensin I–converting enzyme 2 (ACE2) and TMPRSS2 have been implicated in influenza and SARS-corona virus (CoV) infection as well as for SARS-CoV-2 in mediating viral entry into the host cell.2 Both genes mediate sex-specific effects with ACE2, located on the X chromosome and TMPRSS2 regulated by androgen (located on 21q22.3). While ACE2 is the main receptor for the spike protein for both viruses, its expression and gene polymorphisms did not influence sex-specific effects or outcomes for SARS3 or COVID-19 (based on 2 recent preprint studies published on medRxiv that have yet to be peer-reviewed at the time of writing).4, 5 TMPRSS2 is an androgen-responsive serine protease that cleaves SARS-CoV-2 spike protein, facilitating viral entry and activation.2 It is expressed in many tissues outside of the lungs6 and is well known for its predominant expression in the prostate epithelium and its role in prostate carcinogenesis.7, 8 The androgen-regulated promoter of TMPRSS2 forms a fusion gene with coding regions of the proto-oncogenic ETS transcription factor family members, which is strongly associated with prostate cancer and regulates many biological processes.9 TMPRSS2 is also expressed on the cardiac endothelium, kidney, and digestive tract, suggesting that these may be important target organs for SARS-CoV-2 infection.6 Indeed, the clinical manifestations of COVID-19 include not only complications from acute myocardial injury, elevated liver enzymes, and acute kidney injury in patients presenting to hospitals, but also gastrointestinal symptoms in community patients experiencing milder forms of the disease.10, 11 Because TMPRSS2 is also expressed on microvascular endothelial cells that line blood vessels,6 viral infection by SARS-CoV-2 may cause endothelial dysfunction, which can lead to thrombosis and associated complications. These data present a rationale for the role of TMP","journal":"The Journal of Clinical Pharmacology","year":2020,"id":55429,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":93,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9322,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":259971,"name":"Cindy H. Chau","orcid":"0000-0002-6928-3833","position":1,"is_corresponding":false},{"id":109200,"name":"William D. Figg","orcid":"0000-0003-2428-5613","position":2,"is_corresponding":false},{"id":259972,"name":"Jonathan D. Strope","orcid":"0000-0001-8247-8427","position":0,"is_corresponding":true}],"reference_count":37,"raw_metadata":null,"created_at":"2026-07-18T21:04:59.506324Z","pmid":"32437018","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}